“Burning sensation on feet and decreased sensationof lower extremity vibration for 2 years”

Yıl 2018, Cilt: 10 Sayı: 6, 25 - 28, 28.11.2018

Emre Bozkırlı

Öz

Abstract

Imagine that you are in a medical competition... They give two clues to the competitor sand want them to find the right diagnosis. These are the clues given to you. The first diagnosis that comes out of your mind is diabetic neuropathy, right? Why do we consider the first diabetic neuropathy, when there are many diseases and conditions that can cause neuropathy and these findings? In this review, I tried to summarize the definition, epidemiology, diagnosis, treatment and follow-up of diabetic neuropathy with the answer tothis question.

Anahtar Kelimeler

Diabetes Mellitus, Diabetic Neuropathies

“2 Yıldır Ayaklarda Yanma Var ve Alt Ekstremite Vibrasyon Hissi Azalmış”

Öz

Öz

Bir tıp yarışmasında olduğunuzu hayal edin… Yarışmacılara iki adet ipucu veriliyor ve doğru tanıyı koymaları isteniyor. Size verilen ipuçları bunlar. Çoğumuzun aklına gelen ilk tanı diyabetik nöropati oluyor değil mi?  Nöropati ve bu bulguları yapabilecek birçok hastalık ve durum varken neden ilk diyabetik nöropatiyi düşünüyoruz? Bu derlemede bu sorunun cevabı ile birlikte diyabetik nöropatinin tanımı, epidemiyolojisi, tanısı, tedavisi ve izlemi konularını özetlemeye çalıştım.

Anahtar Kelimeler

Diabetes Mellitus, Diyabetik Nöropati

Kaynakça

• Kaynaklar 1.Vas PRJ, Edmonds ME. Earlyrecognition of diabeticperiphe-ralneuropathyandtheneedforone-stop microvascularassess-ment.LancetDiabetesEndocrinol. 2016 Sep;4(9):723-725. 2.Dimova R, Tankova T, Guergueltcheva V, Tournev I, Chaka-rova N, Grozeva G, et al. Risk factorsforautonomicandsoma-ticnervedysfunction in differentstages of glucosetolerance.J Dia-betesComplications. 2017 Mar;31(3):537-543. 3.Ziegler D, Papanas N, Vinik AI, Shaw JE. Epidemiology of polyneuropathy in diabetesandprediabetes.HandbClinNeurol.2014;126:3-22. 4.Papanas N, Ziegler D. Risk FactorsandComorbidities in Dia-beticNeuropathy: An Update 2015.RevDiabetStud. 2015Spring-Summer;12(1-2):48-62. 5.Shaw JE, Hodge AM, de Courten M, DowseGK, Gareeboo H,Tuomilehto J, et al. Diabeticneuropathy in Mauritius: preva-lenceand risk factors.DiabetesResClinPract. 1998Nov;42(2):131-9. 6.Morrison S, Colberg SR, Parson HK, Vinik AI.Relationbetwe-en risk of fallingandposturalswaycomplexity in diabetes.Ga-itPosture. 2012 Apr;35(4):662-8. 7.Boulton AJ.Thepathwaytofootulceration in diabetes.MedClinNorth Am. 2013 Sep;97(5):775-90. 8.Perkins BA, Olaleye D, Zinman B, Bril V.Simple screening-testsforperipheralneuropathy in thediabetesclinic.DiabetesCa-re. 2001 Feb;24(2):250-6. 9.Callaghan BC, Kerber KA, Lisabeth LL, Morgenstern LB, Lon-goria R, Rodgers A,et al.Role of neurologistsanddiagnostic-tests on themanagement of distalsymmetricpolyneuropathy.JAMA Neurol. 2014 Sep;71(9):1143- 10.Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N,Greene DA.A practicaltwo-step quantitativeclinicalandelect-rophysiologicalassessmentforthediagnosisandstaging of dia-beticneuropathy.DiabetesCare. 1994 Nov;17(11):1281-9. 11.Diabetes Control and Complications Trial Research Group,Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Da-vis M, et al.Theeffect of intensivetreatment of diabetes on the-developmentandprogression of long-term complications in in-sulin-dependent diabetesmellitus.N Engl J Med. 1993 Sep30;329(14):977-86. 12.UK ProspectiveDiabetesStudy (UKPDS) Group.Intensiveblo-od-glucosecontrolwithsulphonylureasorinsulincomparedwith-conventionaltreatmentand risk of complications in patients-withtype 2 diabetes (UKPDS 33).Lancet. 1998 Sep12;352(9131):837-53. 13.Diabetes Control and Complications Trial Research Group.Effect of intensive diabetes treatment on nerveconduction inthe Diabetes Control and Complications Trial.AnnNeurol. 1995Dec;38(6):869-80. 14.Callaghan BC, Little AA, Feldman EL, Hughes RA.Enhancedg lucosecontrolforpreventingand treatingdiabeticneuropathy. Cochrane Database SystRev. 2012 Jun 13;(6):CD007543. doi:10.1002/14651858. 15.Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Ma-lik RA, et al.DiabeticNeuropathy: A Position StatementbytheAmericanDiabetesAssociation.DiabetesCare. 2017Jan;40(1):136-154. 16.Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R.Ef-fects of desipramine, amitriptyline, andfluoxetine on pain in dia-beticneuropathy.N Engl J Med. 1992 May 7;326(19):1250-6. 17.Lunn MP, Hughes RA, Wiffen PJ.Duloxetinefortreatingpain-fulneuropathyorchronicpain.Cochrane Database SystRev.2009 Oct 7;(4):CD007115. 18.Rowbotham MC, Goli V, Kunz NR, Lei D.Venlafaxineexten-dedrelease in thetreatment of painfuldiabeticneuropathy: a do-uble-blind, placebo-controlledstudy.Pain. 2004 Aug;110(3):697-706. 19.Backonja MM.Use of anticonvulsantsfortreatment of neuro-pathicpain.Neurology. 2002 Sep 10;59(5 Suppl 2):S14-7.20.Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, LitchyWJ, et al; SYDNEY Trial StudyGroup.Thesensorysymptoms ofdiabeticpolyneuropathyareimprovedwithalpha-lipoicacid: theSYDNEY trial.DiabetesCare. 2003 Mar;26(3):770-6. 21.Bril V, England JD, Franklin GM, Backonja M, Cohen J, DelToro D, et al; American Academy of Neurology; AmericanAs-sociation of Neuromuscularand Electrodiagnostic Medicine;American Academy of PhysicalMedicineand Rehabilitation.Evi-dence-basedguideline: Treatment of painfuldiabeticneuropathy:report of theAmerican Academy of Neurology, theAmericanAs-sociation of NeuromuscularandElectrodiagnosticMedicine,andtheAmerican Academy of PhysicalMedicineandRehabili-tation.MuscleNerve. 2011 Jun;43(6):910-7.